Trial Profile
A Multi-Center, Double-Masked, Randomized, Vehicle- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Bilastine Ophthalmic Solution 0.6% Compared to Vehicle and Zaditen (Ketotifen Ophthalmic Solution 0.025%) for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC) Model
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Dec 2021
Price :
$35
*
At a glance
- Drugs Bilastine (Primary) ; Ketotifen
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Acronyms Ora-CAC
- Sponsors FAES Farma
- 25 Oct 2018 Status changed from recruiting to completed.
- 02 Apr 2018 New trial record